lusvertikimab,bi 765063
ose immunotherapeutics,servier,boehringer ingelheim
['ose-127', 'bi 765063', 'oseimmuno']
we present clinical and preclinical updates from our io pipeline at the 2023 american association for cancer research (aacr) including anti-sirp bi 765063, anti-il-7r antagonist ose-127 in hematology and bispecific anti-pd1/il-7 bicki -il-7. read: 
focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immune-oncology and auto-immune diseases.